Cochlear Limited

Report azionario ASX:COH

Capitalizzazione di mercato: AU$8.0b

Cochlear Crescita futura

Criteri Future verificati 1/6

Cochlear prevede che gli utili e i ricavi cresceranno rispettivamente di 7.4% e 4.2% all'anno. Si prevede che l'EPS crescerà di 7.1% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 18.2% in 3 anni.

Informazioni chiave

7.4%

Tasso di crescita degli utili

7.07%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili13.4%
Tasso di crescita dei ricavi4.2%
Rendimento futuro del capitale proprio18.17%
Copertura analitica

Good

Ultimo aggiornamento10 Jul 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento narrativa • Jul 02

COH: Hospital Bottlenecks And Weaker Referrals Will Pressure Earnings Expectations

The analyst price target for Cochlear has been revised from A$210 to A$95, reflecting updated expectations for revenue growth, profit margins, the discount rate and future P/E as outlined in recent Street research from multiple analysts. Analyst Commentary Recent Street research on Cochlear highlights a more cautious tone despite mixed rating actions, with several bearish analysts questioning how well the current share price lines up with the revised A$95 target and the company’s execution risks.
Articolo di analisi • Jun 19

Cochlear (ASX:COH) Shares Could Be 44% Below Fair Value After 2026 Guidance Cut

Cochlear (ASX:COH) is back in focus after the company issued a 2026 guidance downgrade, prompting a reset in expectations for both the stock and the broader premium ASX healthcare segment. See our latest analysis for Cochlear. The 2026 guidance downgrade comes after a sharp rebound in Cochlear’s share price over the past month, with a 30 day share price return of 24.66%. However, that short term strength contrasts with a much weaker backdrop, including a 90 day share price decline of 28.23%...
Aggiornamento narrativa • Jun 18

COH: Margin Resilience And Core Franchise Strength Will Support Future Upside

The analyst price target for Cochlear has been adjusted slightly lower to A$124.40. Analysts attribute this change to modest tweaks in the discount rate, revenue growth, profit margin and future P/E assumptions following recent mixed research updates from major brokers.
Aggiornamento narrativa • Jun 03

COH: Margin Resilience And Temporary Volume Weaknesses Will Support Future Upside

The analyst price target for Cochlear has eased slightly from about A$126.08 to A$124.60, as analysts factor in more moderate revenue growth expectations alongside marginally stronger profit margins and a slightly lower assumed future P/E, following mixed recent research views. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside if Cochlear can deliver on revenue expectations while maintaining the marginally stronger profit margins now being reflected in models.
Aggiornamento narrativa • May 09

COH: Steadier Growth Assumptions Will Support Future Upside If Execution Holds

The updated analyst price target for Cochlear has shifted from A$239.95 to A$126.08 as analysts incorporate more moderate assumptions for revenue growth, profit margins and future P/E. This reflects mixed recent research views from Citi and Morgan Stanley.
Nuova narrativa • May 09

Cochlear’s Crossroads: Temporary Setback or Structural Shift?

Cochlear Limited is an interesting company. It is a medical technology business with a specific focus on implantable hearing solutions.
Aggiornamento narrativa • Apr 21

COH: VA Access Expansion Will Support Future Upside Despite Slight Model Adjustments

The Analyst Price Target for Cochlear has been adjusted slightly lower to A$239.95 from A$244.58, as analysts now factor in modestly softer revenue growth, profit margin and future P/E assumptions, along with a slightly higher discount rate. Valuation Changes Fair Value: adjusted slightly lower from A$244.58 to A$239.95.
Aggiornamento narrativa • Apr 04

COH: VA Access Expansion And Upgraded Coverage Will Underpin Future Upside

Analysts have slightly adjusted their price target for Cochlear to A$244.58 from A$245.91. This reflects updated assumptions around discount rates and valuation multiples, while core growth and profitability expectations remain broadly unchanged.
Aggiornamento narrativa • Mar 21

COH: VA Access Expansion Will Support Future Upside Potential

Analysts have adjusted their price target on Cochlear slightly lower to A$245.91 from A$250.59, reflecting modest tweaks to assumptions around the discount rate, revenue growth, profit margins and future P/E following recent research updates. Analyst Commentary Bullish Takeaways Bullish analysts see the revised A$245.91 target as still supportive of upside potential relative to recent trading levels, suggesting the core earnings story remains intact despite the small adjustment.
Aggiornamento narrativa • Mar 06

COH: Steady Assumptions And New Access Channels Will Support Future Upside Potential

Analysts have reaffirmed their A$250.59 price target for Cochlear, citing recent research that supports steady assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent research behind the reaffirmed A$250.59 price target highlights a mix of supportive factors and watchpoints that matter for Cochlear's valuation and execution risk.
Nuova narrativa • Mar 01

Cloud And R&D Investment Will Pressure Margins While Long Term Hearing Demand Supports Stability

Catalysts About Cochlear Cochlear develops and manufactures hearing implant systems for people with severe to profound hearing loss. What are the underlying business or industry changes driving this perspective?
Aggiornamento narrativa • Feb 20

COH: Reset Expectations And Product Adoption Will Support Future Upside Potential

Analysts have trimmed their Cochlear price target from A$301.76 to A$250.59 as they factor in slightly lower revenue growth assumptions, a marginally higher discount rate, modestly softer profit margin expectations and a reduced future P/E multiple, as highlighted in recent Street research, including the latest upgrade at RBC Capital. Analyst Commentary Recent Street commentary around Cochlear focuses on how current expectations stack up against its A$250.59 target price and what needs to go right, or wrong, for that valuation to hold.
Articolo di analisi • Feb 16

Cochlear (ASX:COH) Has Affirmed Its Dividend Of A$2.15

Cochlear Limited's ( ASX:COH ) investors are due to receive a payment of A$2.15 per share on 13th of April. This means...
Articolo di analisi • Feb 15

Some Confidence Is Lacking In Cochlear Limited (ASX:COH) As Shares Slide 26%

Cochlear Limited ( ASX:COH ) shareholders that were waiting for something to happen have been dealt a blow with a 26...
Nuova narrativa • Feb 13

Hearing Health Tailwinds And Cloud Capabilities Will Support Multi Year Earnings Expansion

Catalysts About Cochlear Cochlear develops and manufactures implantable hearing solutions for people with severe to profound hearing loss. What are the underlying business or industry changes driving this perspective?
Articolo di analisi • Feb 06

Here's Why We Think Cochlear (ASX:COH) Might Deserve Your Attention Today

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Aggiornamento narrativa • Feb 05

COH: Execution Upside And Premium P/E Will Underpin Future Upside Potential

Analysts have trimmed their price target on Cochlear to about A$302 from roughly A$305, reflecting a slightly higher discount rate, modestly lower revenue growth assumptions, and a small uplift in expected profit margins and future P/E multiples. Analyst Commentary Recent research adjustments on Cochlear point to a generally constructive stance, with the trimmed price target tied to updated assumptions rather than a material change in the long term story.
Articolo di analisi • Jan 11

Investors Shouldn't Overlook Cochlear's (ASX:COH) Impressive Returns On Capital

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Articolo di analisi • Nov 18

Risks To Shareholder Returns Are Elevated At These Prices For Cochlear Limited (ASX:COH)

When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 21x, you may consider...
Articolo di analisi • Oct 14

Does Cochlear (ASX:COH) Deserve A Spot On Your Watchlist?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Articolo di analisi • Sep 28

We Think Cochlear (ASX:COH) Might Have The DNA Of A Multi-Bagger

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Aggiornamento narrativa • Sep 19

Aging Population Will Spur Cochlear Implant Adoption Worldwide

Cochlear’s modestly lower consensus price target predominantly reflects a slight reduction in forecast revenue growth, resulting in a revised fair value estimate of A$305.38. What's in the News Cochlear extended its share buyback plan duration to August 28, 2026.
Articolo di analisi • Aug 26

Cochlear (ASX:COH) Is Due To Pay A Dividend Of A$2.15

Cochlear Limited's ( ASX:COH ) investors are due to receive a payment of A$2.15 per share on 13th of October. This...
Aggiornamento narrativa • Aug 19

New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects

Cochlear’s consensus price target has been revised upward, primarily reflecting improved revenue growth forecasts and a slight increase in net profit margin, resulting in a new fair value estimate of A$309.91. What's in the News FDA approved Cochlear’s Nucleus Nexa System, the first smart cochlear implant system with upgradeable firmware, allowing recipients to access future innovations through both the implant and sound processor.
Articolo di analisi • Jul 16

Cochlear Limited's (ASX:COH) Shares May Have Run Too Fast Too Soon

When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 18x, you may consider...
User avatar
Nuova narrativa • Feb 23

New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects

Focus on adult and senior markets in developed countries could drive revenue and net margin growth through increased sales volume.

Previsioni di crescita degli utili e dei ricavi

ASX:COH - Stime future degli analisti e dati finanziari passati (AUD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
6/30/20292,6784064094913
6/30/20282,57237435147115
6/30/20272,41132433043716
6/30/20262,32224125239116
12/31/20252,339345166265N/A
9/30/20252,341367150251N/A
6/30/20252,343389135238N/A
3/31/20252,326380193290N/A
12/31/20242,309371251342N/A
9/30/20242,272364275365N/A
6/30/20242,236357299389N/A
3/31/20242,193354317410N/A
12/31/20232,149350335430N/A
9/30/20232,043326301396N/A
6/30/20231,936301267362N/A
3/31/20231,824281263352N/A
12/31/20221,713261259341N/A
9/30/20221,681275279359N/A
6/30/20221,648289299377N/A
3/31/20221,612273266340N/A
12/31/20211,575257233304N/A
9/30/20211,536291216285N/A
6/30/20211,498324199265N/A
3/31/20211,40382-5234N/A
12/31/20201,308-160-302-198N/A
9/30/20201,314-199-295-178N/A
6/30/20201,321-238-288-158N/A
3/31/20201,40034-8050N/A
12/31/20191,479306128259N/A
9/30/20191,453291N/A277N/A
6/30/20191,427277N/A296N/A
3/31/20191,422270N/A313N/A
12/31/20181,418264N/A330N/A
9/30/20181,391255N/A294N/A
6/30/20181,364246N/A258N/A
3/31/20181,329234N/A254N/A
12/31/20171,294223N/A250N/A
9/30/20171,274223N/A255N/A
6/30/20171,254224N/A260N/A
3/31/20171,218215N/A237N/A
12/31/20161,182206N/A214N/A
9/30/20161,156198N/A199N/A
6/30/20161,131189N/A185N/A
3/31/20161,088179N/A179N/A
12/31/20151,045168N/A172N/A
9/30/2015986157N/A181N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di COH ( 7.4% all'anno) è superiore al tasso di risparmio ( 3.6% ).

Guadagni vs Mercato: Si prevede che gli utili di COH ( 7.4% all'anno) cresceranno più lentamente rispetto al mercato Australian ( 11.5% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di COH cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di COH ( 4.2% all'anno) crescerà più lentamente rispetto al mercato Australian ( 5.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di COH ( 4.2% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di COH sarà basso tra 3 anni ( 18.2 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/07/13 12:57
Prezzo dell'azione a fine giornata2026/07/13 00:00
Utili2025/12/31
Utili annuali2025/06/30

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Cochlear Limited è coperta da 26 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Saul HadassinBarrenjoey Markets Pty Limited
Stuart RobertsBell Potter
Elisabeth Decou CliveBernstein